David Gailani

List of Publications by Citations

Source: https://exaly.com/author-pdf/1505723/david-gailani-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers5,460
citations34
h-index72
g-index145
ext. papers6,467
ext. citations7.4
avg, IF5.73
L-index

#	Paper	IF	Citations
136	Factor XI activation in a revised model of blood coagulation. <i>Science</i> , 1991 , 253, 909-12	33.3	654
135	Defective thrombus formation in mice lacking coagulation factor XII. <i>Journal of Experimental Medicine</i> , 2005 , 202, 271-81	16.6	528
134	Factor XI antisense oligonucleotide for prevention of venous thrombosis. <i>New England Journal of Medicine</i> , 2015 , 372, 232-40	59.2	358
133	Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 513-8	16.6	344
132	Intrinsic pathway of coagulation and arterial thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2507-13	9.4	199
131	Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 695-702	15.4	199
130	A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. <i>Blood</i> , 2010 , 116, 398	1 <u>=9</u> 2	185
129	Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. <i>Blood</i> , 2011 , 118, 5302-11	2.2	159
128	Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. <i>Blood</i> , 2009 , 113, 936-44	2.2	153
127	Factor XII inhibition reduces thrombus formation in a primate thrombosis model. <i>Blood</i> , 2014 , 123, 173	9-24.6	152
126	The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 1106-12	15.4	152
125	Factor XI contributes to thrombin generation in the absence of factor XII. <i>Blood</i> , 2009 , 114, 452-8	2.2	110
124	A murine model of factor XI deficiency. Blood Coagulation and Fibrinolysis, 1997, 8, 134-44	1	97
123	Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 1670-8	9.4	95
122	Evolution of the contact phase of vertebrate blood coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1876-83	15.4	85
121	Factor XI and contact activation as targets for antithrombotic therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1383-95	15.4	82
120	Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. <i>Blood</i> , 2012 , 119, 4762-8	2.2	73

119	Why factor XI deficiency is a clinical concern. Expert Review of Hematology, 2016, 9, 629-37	2.8	65
118	An update on factor XI structure and function. <i>Thrombosis Research</i> , 2018 , 161, 94-105	8.2	63
117	Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. <i>Journal of Immunology</i> , 2011 , 187, 1866-76	5.3	59
116	Factor XI as a Therapeutic Target. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 1316-22	9.4	59
115	Excess of heme induces tissue factor-dependent activation of coagulation in mice. <i>Haematologica</i> , 2015 , 100, 308-14	6.6	58
114	Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1341-52	15.4	58
113	Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation. <i>Blood</i> , 2017 , 129, 1527-1537	2.2	53
112	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. <i>JAMA Oncology</i> , 2017 , 3, 980-988	13.4	53
111	Activation of factor XI by products of prothrombin activation. <i>Blood</i> , 2011 , 118, 437-45	2.2	51
110	Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1295-301	15.4	48
109	Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. <i>Journal of Infectious Diseases</i> , 2008 , 198, 271-4	7	48
108	A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. <i>Thrombosis Research</i> , 2016 , 140, 118-124	8.2	43
107	Structural and functional features of factor XI. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7 Suppl 1, 75-8	15.4	43
106	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 799-809	9.4	37
105	Evidence for factor[IX-independent roles for factor[XIa in blood coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 2118-27	15.4	37
104	The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1099-114	3.1	36
103	Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. <i>PLoS ONE</i> , 2016 , 11, e0152968	3.7	35
102	Factor XI Messenger RNA in Human Platelets. <i>Blood</i> , 1999 , 94, 3397-3404	2.2	34

101	Plasma contact factors as therapeutic targets. <i>Blood Reviews</i> , 2018 , 32, 433-448	11.1	30
100	Factor XI as a target for antithrombotic therapy. <i>Drug Discovery Today</i> , 2014 , 19, 1454-8	8.8	30
99	Factor XI anion-binding sites are required for productive interactions with polyphosphate. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 2020-8	15.4	30
98	Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 60-69	5.3	29
97	Inhibition of contact-mediated activation of factor XI protects baboons against -induced organ damage and death. <i>Blood Advances</i> , 2019 , 3, 658-669	7.8	29
96	A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. <i>Blood</i> , 2019 , 133, 1152-1163	2.2	29
95	Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 671-681	7	28
94	Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibibinding and heparin-binding site of thrombin. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 828-38	15.4	28
93	Generation and characterization of aptamers targeting factor XIa. <i>Thrombosis Research</i> , 2017 , 156, 134	-1841	27
92	The mechanism underlying activation of factor IX by factor XIa. <i>Thrombosis Research</i> , 2014 , 133 Suppl 1, S48-51	8.2	27
91	Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. <i>Infection and Immunity</i> , 2012 , 80, 91-9	3.7	26
90	The Role of Factor XI in Coagulation. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 072-074	7	26
89	Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. <i>Thrombosis Research</i> , 2015 , 136, 379-87	8.2	25
88	The contact activation system as a potential therapeutic target in patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 500-505	5.1	24
87	Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 475-81	9.4	24
86	Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. <i>Journal of Immunology</i> , 2013 , 190, 4149-61	5.3	24
85	Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. <i>Journal of Leukocyte Biology</i> , 2011 , 90, 923-7	6.5	24
84	Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 510-7	9.4	23

83	Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome. <i>Blood</i> , 2000 , 96, 1191-1193	2.2	23
82	Anticoagulant-induced skin necrosis in a patient with hereditary deficiency of protein S. <i>American Journal of Hematology</i> , 1999 , 60, 231-6	7.1	22
81	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1748-176	6 0 4	21
80	Future prospects for contact factors as therapeutic targets. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 52-9	3.1	18
79	Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways. <i>Blood</i> , 2018 , 132, 849-860	2.2	18
78	The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. <i>Blood</i> , 2005 , 106, 3055-7	2.2	17
77	Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI. <i>PLoS ONE</i> , 2016 , 11, e0165172	3.7	17
76	SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. <i>ELife</i> , 2021 , 10,	8.9	16
75	Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 205-216	5.1	15
74	Do platelets synthesize factor XI?. Journal of Thrombosis and Haemostasis, 2004, 2, 1709-12	15.4	14
73	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021 , 385, 2161-2172	59.2	14
72	Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor). <i>Current Molecular Medicine</i> , 2014 , 14, 1173-85	2.5	14
71	Polyphosphate, Zn and high molecular weight kininogen modulate individual reactions of the contact pathway of blood clotting. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2131-2140	15.4	13
70	Mouse models of hemostasis. <i>Platelets</i> , 2020 , 31, 417-422	3.6	11
69	A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect. Journal of Thrombosis and Haemostasis, 2007 , 5, 781-7	15.4	11
69 68	Journal of Thrombosis and Haemostasis, 2007 , 5, 781-7	15.4 2.2	11
	Journal of Thrombosis and Haemostasis, 2007 , 5, 781-7	2.2	

65	Effects of glycosaminoglycans on factor XI activation by thrombin. <i>Blood Coagulation and Fibrinolysis</i> , 1993 , 4, 15-20	1	10
64	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2021 , 78, 625-631	15.1	10
63	Factor[XI promotes hemostasis in factor[IX-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 2044-2049	15.4	9
62	Protease activity in single-chain prekallikrein. <i>Blood</i> , 2020 , 135, 558-567	2.2	9
61	Phenotype of ribonuclease 1 deficiency in mice. <i>Rna</i> , 2019 , 25, 921-934	5.8	8
60	Rare Coagulation Factor Deficiencies 2018 , 2034-2050		8
59	Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	8
58	Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1001-1017	15.4	8
57	Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions. <i>Frontiers in Medicine</i> , 2017 , 4, 232	4.9	7
56	Coagulation factor XII contributes to hemostasis when activated by soil in wounds. <i>Blood Advances</i> , 2020 , 4, 1737-1745	7.8	6
55	Nomenclature of factor XI and the contact system. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2216-2219	15.4	6
54	Factor IX binding to collagen. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1840-2	15.4	6
53	The evolution of factor XI and the kallikrein-kinin system. <i>Blood Advances</i> , 2020 , 4, 6135-6147	7.8	6
52	The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. <i>Blood</i> , 2021 , 138, 2173-2184	2.2	6
51	Factor XI contributes to myocardial ischemia-reperfusion injury in mice. <i>Blood Advances</i> , 2018 , 2, 85-88	7.8	6
50	Advances and dilemmas in factor XI. Current Opinion in Hematology, 1994, 1, 347-53	3.3	6
49	The rebirth of the contact pathway: a new therapeutic target. <i>Current Opinion in Hematology</i> , 2020 , 27, 311-319	3.3	5
48	Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus. <i>Blood</i> , 2021 , 138, 178-189	2.2	5

(2018-2019)

47	A non-circulating pool of factor XI associated with glycosaminoglycans in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1449-1460	15.4	4
46	Activity of Factor XII-Locarno. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 168-173	5.1	4
45	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). <i>Thrombosis Research</i> , 2015 , 136 Suppl 1, S13-8	8.2	4
44	A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021 ,	15.4	4
43	Murine models in the evaluation of heparan sulfate-based anticoagulants. <i>Methods in Molecular Biology</i> , 2015 , 1229, 483-96	1.4	4
42	Toward a better understanding of factor XI activation. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2016-2018	15.4	4
41	Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor. <i>Blood Advances</i> , 2020 , 4, 207-216	7.8	4
40	Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H. <i>Journal of Immunology</i> , 2021 , 206, 1784-1792	5.3	3
39	Factor IX for treating factor XI deficiency?. Blood, 2019, 134, 501-502	2.2	3
38	Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis. <i>Cellular and Molecular Bioengineering</i> , 2021 , 14, 161-175	3.9	3
37	Proteolytic activity of contact factor zymogens. Journal of Thrombosis and Haemostasis, 2021, 19, 330-3	8 41 5.4	3
36	Dilutional coagulopathy in pediatric scoliosis surgery: A single center report. <i>Paediatric Anaesthesia</i> , 2018 , 28, 974-981	1.8	3
35	Factor XI Deficiency or Hemophilia C 2014 , 71-81		2
34	Characterization of Heparin Binding Site Residues on the Catalytic Domain of Factor XIa. <i>Blood</i> , 2008 , 112, 1018-1018	2.2	2
33	An Analysis of Cleavage of the Factor IX Activation Sites by Factor XIa. <i>Blood</i> , 2008 , 112, 3088-3088	2.2	2
32	Feedback Activation of Factor XI by Thrombin Is Essential for Hemostasis In Vivo <i>Blood</i> , 2009 , 114, 212	27 <u>2-2</u> 12	7 2
31	Antibodies to Human Factor XII with Antithrombotic Properties. <i>Blood</i> , 2012 , 120, 1106-1106	2.2	2
30	Factor XI and pulmonary infections. <i>Haemophilia</i> , 2018 , 24, 519-521	3.3	2

29	The clinical management of factor XI deficiency in pregnant women. <i>Expert Review of Hematology</i> , 2020 , 13, 719-729	2.8	1
28	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation <i>Journal of Biological Chemistry</i> , 2022 , 101567	5.4	1
27	Structural and Functional Significance of Amino Acid Lysine192 (chymotrypsin numbering) in Factor XIa and Factor VIIa <i>Blood</i> , 2008 , 112, 2030-2030	2.2	1
26	Factor XI Contributes to Thrombin Generation in the Absence of Factor XIIa. <i>Blood</i> , 2008 , 112, 3082-308	2 .2	1
25	FXII Promotes Coagulation in a FXI and FIX Independent Manner. <i>Blood</i> , 2012 , 120, 3362-3362	2.2	1
24	Factor XI Deficiency Reduces The Inflammatory Response To Polymicrobial Sepsis In Mice. <i>Blood</i> , 2013 , 122, 201-201	2.2	1
23	Murine Models in the Evaluation of Heparan Sulfate-Based Anticoagulants. <i>Methods in Molecular Biology</i> , 2022 , 2303, 789-805	1.4	1
22	Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome. <i>Blood</i> , 2000 , 96, 1191-1193	2.2	1
21	Factor XI Deficient Mice Have Reduced Platelet Accumulation and Fibrin Deposition after Laser Injury <i>Blood</i> , 2004 , 104, 218-218	2.2	1
20	Effect of Factor XI or Factor IX Deficiency on an Arterial Occlusion Model <i>Blood</i> , 2004 , 104, 3501-3501	2.2	1
19	Role of platelets in regulating activated coagulation factor XI activity. <i>American Journal of Physiology - Cell Physiology</i> , 2021 , 320, C365-C374	5.4	1
18	A multifaceted investigation into molecular associations of chronic thromboembolic pulmonary hypertension pathogenesis. <i>JRSM Cardiovascular Disease</i> , 2020 , 9, 2048004020906994	1.1	Ο
17	Making anticoagulation safer Lancet, The, 2022, 399, 1360-1361	40	0
16	A Common Missense Variant Causing Factor XI Deficiency and Increased Bleeding Tendency in Maine Coon Cats. <i>Genes</i> , 2022 , 13, 792	4.2	Ο
15	Making thrombolysis safer in stroke. <i>Blood</i> , 2017 , 129, 2212-2213	2.2	
14	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. <i>Blood</i> , 2021 , 138, 441-441	2.2	
13	Independence of Factor XIa Subunits in Factor IX Activation <i>Blood</i> , 2006 , 108, 334-334	2.2	
12	Factor XI Deficiency Confers a Survival Advantage in a Murine Sepsis Model <i>Blood</i> , 2006 , 108, 1005-100) 5 .2	

LIST OF PUBLICATIONS

11	Identification of a Role for Apolipoprotein E Receptor 2 as a Platelet Receptor for Factor XI. <i>Blood</i> , 2008 , 112, 3914-3914	2.2
10	Factor XI Inhibitor Antibody Treatment Improves Survival In a Murine Polymicrobial Sepsis Model. <i>Blood</i> , 2010 , 116, 820-820	2.2
9	Activation of Factor XI and the Contact Proteases by Products of Prothrombin Activation <i>Blood</i> , 2010 , 116, 1150-1150	2.2
8	Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates. <i>Blood</i> , 2011 , 118, 1173-1173	2.2
7	Coagulation Cofactor Presentation and Complex Assembly on Platelets by Protease Activated Receptors (PARs): PAR4 Stimulation Leads to More FV and FVIII and More Thrombin Generation Than PAR1. <i>Blood</i> , 2011 , 118, 1135-1135	2.2
6	Exosite Interactions in Factor IX Activation by Factor XIa. <i>Blood</i> , 2011 , 118, 2235-2235	2.2
5	Evidence for a Factor IX-Independent Role for Factor XI in Thrombin Generation. <i>Blood</i> , 2011 , 118, 224	4- <u>2.2</u> 44
4	Deficiency in Plasminogen Cause Decreased Vascularity in Sold Tissue Organs and Bone. <i>Blood</i> , 2011 , 118, 857-857	2.2
3	Antisense Oligonucleotide Mediated Depletion of Factor XI Prevents Vascular Occlusion in An Experimental Thrombosis Model in Primates. <i>Blood</i> , 2011 , 118, 2250-2250	2.2
2	The Interaction of Coagulation Factor XI with Polyphosphate. <i>Blood</i> , 2012 , 120, 498-498	2.2

George J. Broze Jr., MD (2 August, 1946¶9 June, 2019). *Thrombosis and Haemostasis*, **2019**, 119, 1889-1890